For UNCOVER-2 and UNCOVER-3 respectively , in the ixekizumab every 2 weeks group , PASI 75 was achieved by 315 ( response rate 897 % ; [ effect size 874 % ( 975 % CI 829-918 ) vs placebo ; 481 % ( 412-550 ) vs etanercept ] ) and 336 ( 873 % ; [ 800 % ( 744-857 ) vs placebo ; 339 % ( 270-407 ) vs etanercept ] ) patients ; in the ixekizumab every 4 weeks group , by 269 ( 775 % ; [ 751 % ( 695-808 ) vs placebo ; 359 % ( 282-436 ) vs etanercept ] ) and 325 ( 842 % ; [ 769 % ( 710-828 ) vs placebo ; 308 % ( 237-379 ) vs etanercept ] ) patients ; in the placebo group , by four ( 24 % ) and 14 ( 73 % ) patients ; and in the etanercept group by 149 ( 416 % ) and 204 ( 534 % ) patients ( all p < 00001 vs placebo or etanercept ) .